Cumberland Pharmaceuticals (CPIX) vs Intercure (INCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Intercure (INCR) over the past year, gaining 90.2% versus a loss of 38.5%. Over five years, CPIX leads with a +154.7% price change compared with -85.4% for INCR. Cumberland Pharmaceuticals is the larger company by market cap ($105.3 million vs $77.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | INCR |
|---|---|---|
| Share price | $7.03 | $5.17 |
| Market cap | $105.33M | $77.57M |
| 1-day change | +0.72% | +2.99% |
| YTD return | +75.38% | +13.63% |
| 1-year return | +90.19% | -38.45% |
| 5-year return | +154.74% | -85.42% |
| Forward P/E | 50.21 | — |
| EPS (TTM) | $-0.62 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.28 | $8.40 |
| 52-week low | $1.85 | $3.40 |
| Distance from 52-week high | -24.25% | -38.45% |
| Average volume | 88.03K | 21.73K |
| Shares outstanding | 14.98M | 15.00M |
| Employees | 88 | 285 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed INCR by 128.6 percentage points over the past year.
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
CPIX vs INCR FAQ
Which is bigger, Cumberland Pharmaceuticals or Intercure?
Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $105.33M compared with $77.57M for Intercure (INCR).
Which stock has performed better over the past year, CPIX or INCR?
CPIX returned +90.19% over the past 12 months, compared with -38.45% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and Intercure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.